Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01428063 · ClinicalTrials.gov registry record · Phase 2
Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 276
- Enrollment target
NCT01428063 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 276 participants.
The verdict
NCT01428063, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 276 participants
- Enrollment target
Study Summary
The purpose of this study is to provide anti-hepatitis C virus drugs to patients who received placebo + peginterferon alfa-2a + ribavirin in prior Bristol-Myers Squibb (BMS) studies and determine whether addition of these drugs results in higher cure rates in patients who previously failed therapy. Approximately 100 genotype 1b patients who received placebo in BMS study NCT01428063 (AI447-028) will receive active drugs in this study.
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- DRUG Pegylated interferon alfa-2a
- DRUG Asunaprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01428063
The ClinicalTrials.gov registry entry for NCT01428063 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ribavirin is the first listed.
NCT01428063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01428063 about?
NCT01428063 is a clinical study titled "Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials". The purpose of this study is to provide anti-hepatitis C virus drugs to patients who received placebo + peginterferon alfa-2a + ribavirin in prior Bristol-Myers Squibb (BMS) studies and determine whether addition of these drugs results in higher cure rates in patients who previously failed therapy. ...
What is the current status of trial NCT01428063?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 276 participants. The study started on 2011-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01428063?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), Pegylated interferon alfa-2a (DRUG), Asunaprevir (DRUG).
Who is sponsoring clinical trial NCT01428063?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.